A first-generation EGFR-TKI, gefitinib, was efficacious in patients with EGFR-positive lung cancer and poor PS [13], but the clinical utility and safety of osimertinib, a third-generation EGFR-TKI, remain unclear. Here, EGFR is linked to lung cancer.